Literature DB >> 24982092

High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.

Nicolas Nesseler1, Marie-Clémence Verdier2, Yoann Launey3, Alexandre Malherbe4, Marine Dermu2, Caroline Piau5, Erwan Flécher6, Olivier Tribut7, Yannick Mallédant3, Philippe Seguin3.   

Abstract

Knowledge regarding antimicrobial therapy strategies in deep sternal wound infections (DSWI) following cardiac surgery is limited. Therefore, we aimed to determine the steady-state plasma and mediastinal concentrations of oxacillin administered by continuous infusion in critically ill patients with DSWI and to compare these concentrations with the susceptibility of staphylococci recovered. A continuous infusion of oxacillin (150 to 200 mg/kg of body weight/24 h) was administered after a loading dose (50 mg/kg). Plasma and mediastinal concentrations of total and unbound oxacillin were determined 4 h after the loading dose (H4) and then at day 1 (H24) and day 2 (H48). Twelve patients were included. Nine patients exhibited bacteremia, 5 were in septic shock, 8 were positive for Staphylococcus aureus, and 4 were positive for coagulase-negative staphylococci. The median MIC (first to third interquartile range) was 0.25 (0.24 to 0.41) mg/liter. Median plasma concentrations of total and unbound oxacillin at H4, H24, and H48 were, respectively, 64.4 (41.4 to 78.5) and 20.4 (12.4 to 30.4) mg/liter, 56.9 (31.4 to 80.6) and 21.7 (6.5 to 27.3) mg/liter, and 57.5 (32.2 to 85.1) and 20 (14.3 to 35.7) mg/liter. The median mediastinal concentrations of total and unbound oxacillin at H4, H24, and H48 were, respectively, 2.3 (0.7 to 25.9) and 0.9 (<0.5 to 15) mg/liter, 29.1 (19.7 to 38.2) and 12.6 (5.9 to 19.8) mg/liter, and 31.6 (14.9 to 42.9) and 17.1 (6.7 to 26.7) mg/liter. High-dose oxacillin delivered by continuous infusion is a valuable strategy to achieve our pharmacokinetic target (4× MIC) at the site of action at H24. But concerns remain in cases of higher MICs, emphasizing the need for clinicians to obtain the MICs for the bacteria and to monitor oxacillin concentrations, especially the unbound forms, at the target site.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24982092      PMCID: PMC4135832          DOI: 10.1128/AAC.02624-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Closed drainage using redon catheters for poststernotomy mediastinitis: results and risk factors for adverse outcome.

Authors:  M Kirsch; A Mekontso-Dessap; R Houël; E Giroud; M L Hillion; D Y Loisance
Journal:  Ann Thorac Surg       Date:  2001-05       Impact factor: 4.330

2.  Pharmacodynamics of cefepime in patients with Gram-negative infections.

Authors:  Vincent H Tam; Peggy S McKinnon; Ronda L Akins; Michael J Rybak; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

Review 3.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

4.  Serial evaluation of the SOFA score to predict outcome in critically ill patients.

Authors:  F L Ferreira; D P Bota; A Bross; C Mélot; J L Vincent
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

Review 5.  Pharmacokinetics of the penicillins in man.

Authors:  M Barza; L Weinstein
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.

Authors:  G M Joynt; J Lipman; C D Gomersall; R J Young; E L Wong; T Gin
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

7.  Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs.

Authors:  O Mimoz; S Soreda; C Padoin; M Tod; O Petitjean; D Benhamou
Journal:  Anesthesiology       Date:  2000-09       Impact factor: 7.892

8.  Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.

Authors:  A Barbot; N Venisse; F Rayeh; S Bouquet; B Debaene; O Mimoz
Journal:  Intensive Care Med       Date:  2003-07-10       Impact factor: 17.440

9.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study.

Authors:  J R Le Gall; S Lemeshow; F Saulnier
Journal:  JAMA       Date:  1993 Dec 22-29       Impact factor: 56.272

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  4 in total

1.  Clinical Outcomes With Continuous Nafcillin Infusions in Children.

Authors:  Chad A Knoderer; Lauren C Karmire; Kristen R Nichols
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

2.  Biofilm infections between Scylla and Charybdis: interplay of host antimicrobial peptides and antibiotics.

Authors:  Sergey Chernysh; Natalia Gordya; Dmitry Tulin; Andrey Yakovlev
Journal:  Infect Drug Resist       Date:  2018-04-09       Impact factor: 4.003

3.  Reactive oxygen species induce antibiotic tolerance during systemic Staphylococcus aureus infection.

Authors:  Sarah E Rowe; Nikki J Wagner; Lupeng Li; Jenna E Beam; Alec D Wilkinson; Lauren C Radlinski; Qing Zhang; Edward A Miao; Brian P Conlon
Journal:  Nat Microbiol       Date:  2019-12-09       Impact factor: 17.745

4.  The mesenchymal stromal cell secretome impairs methicillin-resistant Staphylococcus aureus biofilms via cysteine protease activity in the equine model.

Authors:  Charlotte Marx; Sophia Gardner; Rebecca M Harman; Gerlinde R Van de Walle
Journal:  Stem Cells Transl Med       Date:  2020-03-26       Impact factor: 6.940

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.